Login to Your Account

Regulatory NEWS
Questioning the FDA's authority to issue a rule that would ultimately put generic drugmakers on the legal hook for "failure-to-warn" claims, several brand and generic companies urged the agency Friday to consider their alternative, which would make the FDA responsible for drug labeling changes once there's generic competition.
The U.S. Supreme Court will hear arguments March 31 in the case of Kimble v. Marvel, a case that tackles the issue of whether royalties necessarily expire when the underlying patent expires.
Glitches in the law that created the 340B drug discount program for safety net health care providers are creating oversight problems and raising questions about the intent of the program.
More Regulatory Headlines

Cast Your Vote

Has biotech’s bubble burst?: